Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 9:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Heparin-induced Thrombocytopenia and Thrombosis Clear all

Conditions: Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
Interventions: Angiomax (bivalirudin) anticoagulant; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Thrombocytopenia
Interventions: Not listed
Lead sponsor: Carelon Research; Other
Eligibility: 6 Months and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 21
States / cities: Atlanta, Georgia • Iowa City, Iowa • New Orleans, Louisiana + 13 more

Conditions: Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis
Interventions: Apixaban; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Heparin-Induced Thrombocytopenia, Thrombosis
Interventions: bivalirudin; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Heparin Induced Thrombocytopenia (HIT)
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Suspected Heparin-Induced Thrombocytopenia
Interventions: Desirudin or Argatroban®; Drug
Lead sponsor: Canyon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Orlando, Florida + 20 more

Conditions: Thrombosis
Interventions: Desirudin; Drug
Lead sponsor: Canyon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 16
States / cities: Aurora, Colorado • Tampa, Florida • Atlanta, Georgia + 12 more

Conditions: Aneurysmal Subarachnoid Hemorrhage, Neurobehavioral Manifestations, Vasospasm, Intracranial, Intracranial Aneurysm, Heparin-induced Thrombocytopenia Type II
Interventions: Continuous Low-Dose IV Unfractionated Heparin Infusion; Drug
Lead sponsor: Robert F. James; Other
Eligibility: 18 Years to 70 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 9
States / cities: New Haven, Connecticut • Gainesville, Florida • Tallahassee, Florida + 6 more

Conditions: Thrombosis, Heparin-induced Thrombocytopenia
Interventions: Fondaparinux; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 1 Year to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Los Angeles, California • Orange, California • Columbus, Ohio + 1 more

Conditions: Heparin-Induced Thrombocytopenia
Interventions: blood samples (2); Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: Orlando, Florida • Houston, Texas

Conditions: Thrombocytopenia, Thrombosis
Interventions: Argatroban; Drug
Lead sponsor: Encysive Pharmaceuticals; Industry
Eligibility: Up to 16 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 13
States / cities: Los Angeles, California • Orange, California • Chicago, Illinois + 9 more

Conditions: Heparin-Induced Thrombocytopenia
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heparin-Induced Thrombocytopenia
Interventions: fondaparinux, warfarin; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Deep Venous Thrombosis
Interventions: Desirudin (Iprivask™), Heparin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Heparin-Induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis Syndrome
Interventions: bivalirudin; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)

Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)

Heparin Induced Thrombocytopenia: Pharmacoeconomics

A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome

Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis

Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin

Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis

Heparin Antibodies in Intensive Care Unit Patients (HAICU)

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

Heparin-Induced Thrombocytopenia Registry

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients